KVL-9
KVL‑9 is an intermediate for constructing KRAS-degrading antibody-drug conjugates (DAC), consisting of a KRAS small-molecule binder, a spacer, a VHL-recruiting ligand, and a cleavable antibody linker. By conjugating with tumor antigen-targeting antibodies, KVL‑9 enables antigen-dependent intracellular delivery and induces VHL‑mediated ubiquitin‑proteasome degradation of KRAS protein. KVL‑9 can be used for the synthesis of DACs. KVL‑9 is applicable to cancer research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 3113309-33-1
- Fòrmula: C140H192F2N38O34S2
- Peso molecular:3053.38
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
KVL-9 achieves antigen-dependent intracellular delivery via conjugation with tumor antigen-targeting antibodies, releases KRAS degrader inside tumor cells, and degrades KRAS protein through the VHL-mediated ubiquitin-proteasome pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 3113309-33-1
-
Peso molecular 3053.38
-
Fòrmula C140H192F2N38O34S2
-
SMILES
C[C@@]1(C2=NC(C3=NC(N4[C@H](CN(CCC4)CCCCOC5=CN(N=N5)[C@@H](C(C)C)C(N6[C@@H](C[C@H](C6)O)C(N[C@H](C7=C(C=C(C8=C(C)N=CS8)C(F)=C7)OCC9=CC=C(C=C9)NC([C@H](C)NC([C@H](C)NC(CCC%10=C(C(F)=C(N%11C(C=CC%11=O)=O)C=C%10)OCCCC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(N(C)CC(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C)=O)=O)C)=NC=C3)=NO2)C%12=C(CCC1)SC(N)=C%12C#N
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. HY-186226-1.pdf
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)